Roivant Sciences Ltd (NASDAQ:ROIV) shares, rose in value on Friday, April 05, with the stock price up by 0.27% to the previous day’s close as strong demand from buyers drove the stock to $11.54.
Actively observing the price movement in the recent trading, the stock is buoying the session at $11.51. The value of beta (5-year monthly) is 1.37 whereas the PE ratio is 2.22 over 12-month period. Referring to stock’s 52-week performance, its high was $13.24, and the low was $6.97. On the whole, ROIV has fluctuated by -0.25% over the past month.
With the market capitalization of Roivant Sciences Ltd currently standing at about $9.30 billion, investors are eagerly awaiting this quarter’s results, scheduled for Jun 26, 2024 – Jul 01, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.3, which is expected to increase to -$0.21 for fiscal year $4.55 and then to about -$1.16 by fiscal year 2025. Data indicates that the EPS growth is expected to be 388.00% in 2025, while the next year’s EPS growth is forecast to be -125.50%.
Analysts have estimated the company’s revenue for the quarter at $33.28 million, with a low estimate of $27.5 million and a high estimate of $40 million. According to the average forecast, sales growth in current quarter could jump up 21.60%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2025, the company’s y-o-y revenues would reach $143.41 million, representing an increase of 134.00% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that ROIV’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium term indicators have put the stock in the category of 100% Buy while long term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of ROIV currently trading nearly 10.15% and 7.15% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 62.44, while the 7-day volatility ratio is showing 5.38% which for the 30-day chart, stands at 4.13%. Furthermore, Roivant Sciences Ltd (ROIV)’s beta value is 1.30, and its average true range (ATR) is 0.46.
A comparison of Roivant Sciences Ltd (ROIV) with its peers suggests the former has fared considerably weaker in the market. ROIV showed an intraday change of 0.27% in today’s session so far, and over the past year, it grew by 62.78%%.
Data on historical trading for Roivant Sciences Ltd (NASDAQ:ROIV) indicates that the trading volumes over the past 10 days have averaged 17.66 million and over the past 3 months, they’ve averaged 7.41 million. According to company’s latest data on outstanding shares, there are 760.14 million shares outstanding.
Nearly 40.16% of Roivant Sciences Ltd’s shares belong to company insiders and institutional investors own 50.51% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 31.57 million shares as on Mar 15, 2024, resulting in a short ratio of 6.07. According to the data, the short interest in Roivant Sciences Ltd (ROIV) stood at 3.92% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 28.77 million. The stock has risen by 2.77% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ROIV stock heading into the next quarter.
